Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas

TY - JOUR

T1 - Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas

AU - Olsen, Ingrid Marie Holst

AU - Sørensen, Jens B

AU - Federspiel, Birgitte

AU - Kjaer, Andreas

AU - Hansen, Carsten P

AU - Knigge, Ulrich

AU - Langer, Seppo W

PY - 2012

Y1 - 2012

N2 - Background. Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results. Patients and Methods. Analysis of consecutive patients with neuroendocrine carcinomas (Ki-67 proliferation index >20) and performance status 02 treated with temozolomide 200 mg/sqm orally days 15 every 28 days after at least one previous platin-containing chemotherapy regimen. Results. Twenty-eight eligible patients received a median of 3 courses. Sixteen patients were evaluable for response: Six achieved stable disease and ten progressed. The median survival for the 28 patients was 3.5 months. Survival in patients with tumors of pancreatic origin (n = 7) was 7.0 months versus 2.9 months in non-pancreatic origin (n = 21). Patients in PS 0-1 (n = 22) had a median survival of 4.5 months versus 1.1 months in patients in PS 2 (n = 6). Ki-67 index ≥50 was associated with a significantly shorter median survival than Ki-67 index 50 (2.7 months versus 10.9 months). The treatment was well tolerated. Conclusion. Temozolomide monotherapy has limited effect in treatment of recurrent neuroendocrine carcinomas. Second line treatment with temozolomide in combination with other compounds should be further investigated in patients in good performance with Ki-67 index 50.

AB - Background. Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results. Patients and Methods. Analysis of consecutive patients with neuroendocrine carcinomas (Ki-67 proliferation index >20) and performance status 02 treated with temozolomide 200 mg/sqm orally days 15 every 28 days after at least one previous platin-containing chemotherapy regimen. Results. Twenty-eight eligible patients received a median of 3 courses. Sixteen patients were evaluable for response: Six achieved stable disease and ten progressed. The median survival for the 28 patients was 3.5 months. Survival in patients with tumors of pancreatic origin (n = 7) was 7.0 months versus 2.9 months in non-pancreatic origin (n = 21). Patients in PS 0-1 (n = 22) had a median survival of 4.5 months versus 1.1 months in patients in PS 2 (n = 6). Ki-67 index ≥50 was associated with a significantly shorter median survival than Ki-67 index 50 (2.7 months versus 10.9 months). The treatment was well tolerated. Conclusion. Temozolomide monotherapy has limited effect in treatment of recurrent neuroendocrine carcinomas. Second line treatment with temozolomide in combination with other compounds should be further investigated in patients in good performance with Ki-67 index 50.

U2 - 10.1100/2012/170496

DO - 10.1100/2012/170496

M3 - Journal article

C2 - 22973169

SN - 2356-6140

VL - 2012

SP - 170496

JO - Scientific World Journal

JF - Scientific World Journal

ER -